Drug Profile
Luzacne
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Luzitin
- Class Antiacnes
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Acne in Portugal
- 03 Aug 2016 Early research in Acne in Portugal (unspecified route)